NASDAQ — Healthcare: Services, Biotechnology: Services-Business Services Nec
www.protagenic.comProtagenic Therapeutics, Inc. is set to file a proxy statement with the Securities and Exchange Commission by September 1, 2025. This filing relates to proposals that include a conversion of certain preferred stock into common stock and a change of control under Nasdaq regulations. The proposals follow the company's recent acquisition of Phytanix Bio, which adds to Protagenic's asset base and reflects on its strategic intent to diversify and strengthen its market positioning. Shareholder approval will be sought in a forthcoming meeting, emphasizing the financial implications of these restructuring initiatives.
Submission of Proxy StatementProtagenic Therapeutics, Inc. is set to file a proxy statement by September 1, 2025, related to a stockholder meeting. The agenda includes proposals for the approval of a share conversion pertaining to newly issued Preferred Stock and a change of control under Nasdaq Listing Rules following the company's acquisition of Phytanix Bio. The planned share exchange agreement aims to issue new common and preferred stock, effectively altering the capital structure post-acquisition. Such a conversion is expected to position Protagenic favorably in the market and is critical for compliance with Nasdaq regulations, with potential implications on shareholder value and dilution.
FilingProtagenic Therapeutics, Inc. has set a deadline of November 3, 2025, for the filing of financial statements related to its recent acquisition of Phytanix Bio through a share exchange agreement concluded on May 15, 2025. The combination, referred to as the "Combination," involved the issuance of common stock and preferred stock to shareholders of Phytanix. Following the transaction, the company expects its stockholders' equity to exceed $2.5 million. This filing is part of the ongoing compliance with financial reporting obligations stemming from the acquisition.
Filing Deadline